Patent EA-002322-B1 (EA)
Title: Tricyclic compounds
Inventor: YOSHIDA MAKOTO
IPC: C07D337/12
Filed: 1998-04-15
Abstract: 1. A tricyclic compound represented by general formula (I):   wherein R<1> represents hydrogen, substituted or unsubstituted (C1-C6) alkyl, substituted or unsubstituted (C1-C6) alkoxy or halogen; X<1>-X<2>-X<3> represents CR<5>=CR<6>-CR<7>=CR<8> (wherein R<5>, R<6>, R<7> and R<8>, which may be the same or different, each represents hydrogen, substituted or unsubstituted (C1-C6) alkyl, hydroxy, substituted or unsubstituted (C1-C6) alkoxy, nitro, amino, mono(C1-C6)alkylamino, di(C1-C6)alkylamino, substituted or unsubstituted (C1-C6) alkanoylamino or halogen), N(O)m=CR<5>-CR<6>=CR<7> (wherein R<5>, R<6> and R<7> have the same significances as defined above, and m represents 0 or 1), CR<5>=CR<6>-N(O)m=CR<7> (wherein R<5>, R<6>, R<7> and m have the same significances as defined above), CR<5>=CR<6>-CR<7>=N(O)m (wherein R<5>, R<6>, R<7> and m have the same significances as defined above), CR<5>=CR<6>-O (wherein R<5> and R<6> have the same significances as defined above), CR<5>=CR<6>-S (wherein R<5> and R<6> have the same significances as defined above), O-CR<7>=CR<8> (wherein R<7> and R<8> have the same significances as defined above), S-CR<7>=CR<8> (wherein R<7> and R<8> have the same significances as defined above) or O-CR<7>=N (wherein R<7> has the same significance as defined above); R<2> represents hydrogen, substituted or unsubstituted (C1-C6) alkyl, substituted or unsubstituted (C2-C6) alkenyl, trifluoromethyl, substituted or unsubstituted (C1-C6) alkoxy, amino, substituted or unsubstituted mono(C1-C6)alkylamino, substituted or unsubstituted di(C1-C6)alkylamino, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkylamino, substituted or unsubstituted arylamino, a substituted or unsubstituted alicyclic heterocyclic group, a substituted or unsubstituted N-containing heterocyclic group or   (wherein n is 0 or 1; R<3> and R<4>, which may be the same or different, each represents hydrogen, substituted or unsubstituted (C1-C6) alkyl, substituted or unsubstituted cyclic alkyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl or trifluoromethyl, or R<3> and R<4> may be combined together to form cyclic alkyl; and Q represents hydroxy, substituted or unsubstituted (C1-C6) alkoxy, amino or halogen), and Y represents -CH2SO2-, -SCH2-, -SOCH2- or -SO2CH2-; and when R<2> does not represent substituted or unsubstituted (C1-C6) alkyl, then Y may represent -OCH2; or a pharmaceutically acceptable salt thereof. 2. A tricyclic compound or a pharmaceutically acceptable salt thereof according to Claim 1, wherein R<1> is hydrogen, substituted or unsubstituted (C1-C6) alkoxy or halogen. 3. A tricyclic compound or a pharmaceutically acceptable salt thereof according to Claim 2, wherein R<1> is hydrogen. 4. A tricyclic compound or a pharmaceutically acceptable salt thereof according to Claim 1, wherein Y is -CH2SO2-, -SO2CH2- or -OCH2-. 5. A tricyclic compound or a pharmaceutically acceptable salt thereof according to Claim 4, wherein Y is -CH2SO2- or -SO2CH2-. 6. A tricyclic compound or a pharmaceutically acceptable salt thereof according to Claim 5, wherein Y is -CH2SO2-. 7. A tricyclic compound or a pharmaceutically acceptable salt thereof according to Claim 1, wherein X<1>-X<2>-X<3> is S-CR<7>=CR<8> (wherein R<7> and R<8> have the same significances as defined above). 8. A tricyclic compound or a pharmaceutically acceptable salt thereof according to Claim 7, wherein R<1> is hydrogen and Y is -CH2SO2-. 9. A tricyclic compound or a pharmaceutically acceptable salt thereof according to Claim 1, wherein X<1>-X<2>-X<3> is CR<5>=CR<6>-CR<7>=CR<8> (wherein R<5>, R<6>, R<7> and R<8> have the same significances as defined above). 10. A tricyclic compound or a pharmaceutically acceptable salt thereof according to Claim 9, wherein R<1> is hydrogen and Y is -CH2SO2-. 11. A tricyclic compound or a pharmaceutically acceptable salt thereof according to any of Claims 1 to 10, wherein R<2> is   (wherein n, R<3>, R<4> and Q have the same significances as defined above). 12. A tricyclic compound or a pharmaceutically acceptable salt thereof according to Claim 11, wherein n is 0. 13. A tricyclic compound or a pharmaceutically acceptable salt thereof according to Claim 12, wherein R<3> is methyl, R<4> is trifluoromethyl, and Q is hydroxy. 14. A tricyclic compound or a pharmaceutically acceptable salt thereof according to Claim 1, wherein R<1> is hydrogen, Y is -CH2SO2-, X<1>-X<2>-X<3> is S-CR<7>=CR<8> (wherein R<7> and R<8> have the same significances as defined above), R<3> is methyl, R<4> is trifluoromethyl, and Q is hydroxy. 15. A pharmaceutical composition comprising a tricyclic compound or a pharmaceutically acceptable salt thereof according to Claim 1.